Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Primary amine oxidase, also referred to as phenylethylamine oxidase or copper amine oxidase in certain bacterial species, is an enzyme that catalyzes the oxidative deamination of primary aromatic amines like phenylethylamine, producing the corresponding aldehyde, ammonia, and hydrogen peroxide. In humans, analogous activity is performed by monoamine oxidase A and monoamine oxidase B, which play crucial roles in neurotransmitter catabolism and are therapeutic targets in neurological and psychiatric disorders. In microorganisms such as Arthrobacter globiformis, this enzyme is copper-dependent and uses topaquinone as a cofactor.
Inhibition of amine oxidase enzymatic activity, resulting in decreased breakdown of amines (such as phenylethylamine) and increased synaptic concentrations
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Primary amine oxidase.